HOLX HOLOGIC INC Insider Trading

CEO MacMillan sells 138,358 shares ($9.3M) at $66.97 avg; holds 1.23M post-sale. Stock -19.2% from 52-week high.

Stephen P. MacMillan, Chairman, President and CEO of Hologic, executed 3 separate sales totaling 138,358 shares for $9,266,117.92 at a blended average price of $66.97 on 2025-09-22, reducing his holdings from 1,372,982 to 1,234,624 shares (-10.1%). The timing context is mixed: at the 90-day horizon, his prior trades at Hologic have been well-timed 75% of the time (3 of 4 prior sells), but the current sale occurs with the stock trading -19.2% from its 52-week high of $83.72 and only -0.9% over the 30-day window, offering limited near-term evidence of a predictive pattern. His cross-ticker track record shows 75.00% well-timed sells at the 90-day mark with an average 90-day return of +0.8%, suggesting his prior sales across all holdings have slightly missed subsequent upside. The company's P/E of 27.06 is elevated relative to its annual revenue growth of -0.0%, and this concentrated single-day disposition of approximately 10% of CEO holdings warrants investor attention to near-term company guidance and operational momentum.

Hologic Director Madaus buys 5,445 shares at $55.24; stock down -32.2% from 52-week high despite positive cross-ticker track record.

Director Martin D Madaus established a new 5,445-share position in HOLX at $55.24, representing his first open-market purchase of this stock. This initial stake arrives amid significant price deterioration: HOLX has fallen 32.2% from its 52-week high of $83.72 and declined 4.3% over the prior 30 days, though the company still trades at a P/E of 22.70 with $1.0B quarterly revenue. Madaus's cross-ticker track record shows 6 prior buys averaging +7.1% returns over 30 days and +12.9% over 90 days with a 100.00% win rate, suggesting consistent judgment in entry timing across his portfolio. However, this HOLX purchase is his first transaction at this ticker, so his track record does not provide evidence of prior accuracy specifically within this security.

Mitchell Essex (COO) sold 24.9K HOLX shares at $76.34 for $1.9M; holdings drop 47.1% to 28.0K shares.

Mitchell Essex, Chief Operating Officer of Hologic, executed a substantial open-market sale of 24,856 shares at $76.34 on 2024-12-04, reducing his holdings by 47.1% from 52.8K to 28.0K shares. The stock has since declined 6.4% over 30 days and 7.6% over 90 days, trading 10.0% below its 52-week high of $83.72. His prior sale at this ticker in November 2023 followed a similar negative subsequent pattern (+2.7% at 90 days, technically positive but not a clear signal). The company generates $1.0B in quarterly revenue with $194.5M in net income, valuing it at $17.1B with a P/E of 16.52. The magnitude of the reduction—nearly half his position—merits monitoring but lacks sufficient pattern data to characterize timing precision.

CFO Oberton sold 52,679 shares (38.5% of holdings) at $80.56; stock down 1.8% in 30d, up 10.6% in 90d

Oberton Karleen Marie, CFO of Hologic, sold 52,679 shares at $80.56 on 2024-08-29, reducing her holdings by 38.5% to 84,042 shares, generating $4.2M in proceeds. The sale occurred near the 52-week high ($83.64), with the current price at $82.16 representing only a 1.8% decline from that peak. Her prior sale at this ticker on 2024-01-29 posted a 90-day return of +1.3%, meaning the stock rose after that sale—poorly-timed by the metric of insider exits. The broader 90-day context here is also mixed: HOLX gained 10.6% in the 90 days prior to this August sale, yet the company faces -17.1% annual revenue growth and a relatively high P/E of 27.21 given the headwind. The sale's timing and magnitude deserve monitoring against forward operating performance.

CEO Macmillan sold 44,039 shares (3 transactions) at $80.60–$82.32 on 2024-07-30 for $3.6M; current price $83.20.

On 2024-07-30, Stephen P. Macmillan, Chairman, President and CEO of Hologic, executed 3 separate sales totaling 44,039 shares for $3,597,924.24, with a blended average price of $81.70. The stock currently trades at $83.20, above the transaction prices, and has appreciated 13.2% over the past 30 days and 8.7% over the past 90 days. Macmillan retains 1,157,562 shares post-transaction, representing a 3.7% reduction in holdings. His prior sell at this ticker on 2023-11-29 showed a positive 90-day return of 7.0%, indicating the stock rose after that sale rather than declining; within this limited same-ticker history, neither of his 1 prior sells was well-timed at the 90-day mark. The company faces headwinds with annual revenue declining 17.1% year-over-year despite a recent quarterly revenue of $1.0B and net income of $194.5M, trading at a P/E of 27.55. The transaction occurs after significant recent price appreciation and does not represent a reduction to minimal holdings.